These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37833963)

  • 21. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
    Jeong MS; Lee KW; Choi YJ; Kim YG; Hwang HH; Lee SY; Jung SE; Park SA; Lee JH; Joo YJ; Cho SG; Ko SG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects for new lung cancer treatments that target EMT signaling.
    Otsuki Y; Saya H; Arima Y
    Dev Dyn; 2018 Mar; 247(3):462-472. PubMed ID: 28960588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling Cellular Signaling Variability Based on Single-Cell Data: The TGFβ-SMAD Signaling Pathway.
    Sarma U; Ripka L; Anyaegbunam UA; Legewie S
    Methods Mol Biol; 2023; 2634():215-251. PubMed ID: 37074581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
    Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
    Elife; 2020 Sep; 9():. PubMed ID: 32897190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapies targeting signaling pathways in lung cancer.
    Yagui-Beltrán A; He B; Raz D; Kim J; Jablons DM
    Thorac Surg Clin; 2006 Nov; 16(4):379-96, vi. PubMed ID: 17240825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
    Niu Z; Jin R; Zhang Y; Li H
    Signal Transduct Target Ther; 2022 Oct; 7(1):353. PubMed ID: 36198685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TGFβ-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling.
    Lu Z; Li Y; Che Y; Huang J; Sun S; Mao S; Lei Y; Li N; Sun N; He J
    Cancer Lett; 2018 Sep; 432():156-168. PubMed ID: 29908210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.
    Kim E; Kim JY; Smith MA; Haura EB; Anderson ARA
    PLoS Biol; 2018 Mar; 16(3):e2002930. PubMed ID: 29522507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth.
    Lecca P; Morpurgo D
    BMC Bioinformatics; 2012; 13 Suppl 14(Suppl 14):S14. PubMed ID: 23095709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting signaling pathways in lung cancer therapy.
    Cho WC
    Expert Opin Ther Targets; 2013 Feb; 17(2):107-11. PubMed ID: 23231077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational approaches for modeling regulatory cellular networks.
    Eungdamrong NJ; Iyengar R
    Trends Cell Biol; 2004 Dec; 14(12):661-9. PubMed ID: 15564042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mathematical models in cancer therapy.
    Jordão G; Tavares JN
    Biosystems; 2017 Dec; 162():12-23. PubMed ID: 28866047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells.
    Nonpanya N; Prakhongcheep O; Petsri K; Jitjaicham C; Tungsukruthai S; Sritularak B; Chanvorachote P
    Anticancer Res; 2020 Sep; 40(9):4989-4999. PubMed ID: 32878787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.
    Curtis LT; van Berkel VH; Frieboes HB
    J Theor Biol; 2018 Jul; 448():38-52. PubMed ID: 29614265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Anti-Cancer Peptide LVTX-8 Inhibits the Proliferation and Migration of Lung Tumor Cells by Regulating Causal Genes' Expression in p53-Related Pathways.
    Zhang P; Yan Y; Wang J; Dong X; Zhang G; Zeng Y; Liu Z
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32498425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitatively Understanding Plant Signaling: Novel Theoretical-Experimental Approaches.
    Samodelov SL; Zurbriggen MD
    Trends Plant Sci; 2017 Aug; 22(8):685-704. PubMed ID: 28668509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical modeling of regulatory networks of intracellular processes - Aims and selected methods.
    Kardynska M; Kogut D; Pacholczyk M; Smieja J
    Comput Struct Biotechnol J; 2023; 21():1523-1532. PubMed ID: 36851915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer systems biology and modeling: microscopic scale and multiscale approaches.
    Masoudi-Nejad A; Bidkhori G; Hosseini Ashtiani S; Najafi A; Bozorgmehr JH; Wang E
    Semin Cancer Biol; 2015 Feb; 30():60-9. PubMed ID: 24657638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.